Physician profile
Ora Burstein
NPI 1205803962
$2,163.70
in general payments reported to CMS, 2019-2025
16 companies · $446 in 2025
The $446 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $88.24 · 2021: $125 · 2022: $184 · 2023: $727 · 2024: $471 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $435.46 | 2021-2024 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $335.97 | 2023-2025 | Hizentra |
| Pfizer INC. | $302.59 | 2019-2025 | |
| Kaleo, INC. | $191.24 | 2019-2024 | Auvi-Q |
| Glaxosmithkline, LLC. | $187.43 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $158.79 | 2022-2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $145.52 | 2025 | Neffy |
| Pharming Healthcare, INC. | $99.54 | 2022-2024 | Ruconest |
| Grifols USA, LLC | $55.14 | 2023-2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $52.81 | 2023-2025 | Cuvitru |
| Aimmune Therapeutics, INC. | $50.78 | 2020 | |
| Novartis Pharmaceuticals Corporation | $43.85 | 2024-2025 | |
| Alk-Abello, INC | $34.59 | 2019-2020 | |
| Genzyme Corporation | $30.38 | 2025 | |
| Amgen INC. | $20.22 | 2024 | Tezspire |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $19.39 | 2024 | Cutaquig |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ora Burstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.